Research programme: inflammatory bowel disease therapeutics - Biora Therapeutics
Latest Information Update: 22 Dec 2023
At a glance
- Originator Progenity
- Developer Biora Therapeutics
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammatory bowel diseases
Most Recent Events
- 19 Dec 2023 Biora Therapeutics receives an Issue Notification from the United States Patent and Trademark Office (USPTO) for NaviCap™ Targeted Oral Delivery Platform
- 15 Aug 2022 Biora Therapeutics has patent protection for targeted delivery localization technology used in the DDS device in USA
- 11 May 2021 Early research in Inflammatory bowel diseases in USA (PO)